ImmunityBio COVID-19 vaccine
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a COVID-19 vaccine developed by the United States-based ImmunityBio.[1][2]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | hAd5 |
Background[edit]
Manufacturing[edit]
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa[3]
ImmunityBio and BioVac plan to distribute the vaccines throughout South African and Africa.[4][5]
Technology[edit]
The vaccine is a Non Replicating Viral Vector[2]
Clinical Research[edit]
Phase I/II[edit]
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa[3][6][7]
Authorizations[edit]
|
Full authorization
Emergency authorization Eligible COVAX recipient (assessment in progress) |
History[edit]
Timeline[edit]
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.[8]
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.[9] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."[9]
References[edit]
- ^ "SA's Biovac to team up with US based ImmunityBio in making its vaccine". BusinessInsider. Retrieved 23 March 2021.
- ^ a b "ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 23 March 2021.
- ^ a b "Covid-19 to Serve as Platform for South African Vaccine Industry". Bloomberg.com. 19 March 2021. Retrieved 20 March 2021.
- ^ Fisher S. "Nzimande excited about vaccine partnership between Biovac & ImmunityBio". ewn.co.za. Retrieved 20 March 2021.
- ^ Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 20 March 2021.
- ^ "ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread". www.businesswire.com. 19 January 2021. Retrieved 23 March 2021.
- ^ Sguazzin A. "SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says". Fin24. Retrieved 23 March 2021.
- ^ Cross R (12 May 2020). "Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?". Chemical & Engineering News. 98 (19).
- ^ a b Cohen J (1 June 2020). "Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests". American Association for the Advancement of Science. Science (magazine).
External links[edit]
 |
Scholia has a profile for ImmunityBio COVID-19 vaccine (Q106616925). |
.svg){kind=small}